Compounded GLP-1
Where a compounded drug parts company with an FDA-approved one, where 503A parts company with 503B, and which accreditation programs tell them apart.
What is Compounded GLP-1?
A GLP-1 prepared from bulk active ingredient by a compounding pharmacy rather than bought as the approved branded product.
It is not an FDA-approved drug: no agency has reviewed that particular preparation for safety, effectiveness or manufacturing quality. This is what most sellers in this register are selling, and the legal ground under it narrowed sharply once FDA declared the shortages over, for tirzepatide in late 2024 and for semaglutide in February 2025. FDA now says 503B outsourcing facilities may not compound either drug from bulk.
Related reading: Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Compounded GLP-1 comes up on this site
On GLP Watchdog, Compounded GLP-1 comes up in 5 research articles, 181 seller reviews, 12 FDA warning letters and 2 tools. Browse the FDA warning letters.
Research that discusses it
- 503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1
- What Is in a Compounded GLP-1 Vial: How to Read the Label
- Compounded GLP-1s and the Adverse Event Reports
- How Much Does Compounded Semaglutide Cost? What Drives the Number
- L-Carnitine Injections for Weight Loss: What the Evidence Shows
Tools that use it
Seller reviews that mention it
Other terms under Pharmacy and drug forms
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers